echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Innovent's GLP-1R/GCGR dual agonist in the treatment of diabetes phase II clinical completed the first case of administration

    Innovent's GLP-1R/GCGR dual agonist in the treatment of diabetes phase II clinical completed the first case of administration

    • Last Update: 2021-09-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 8, Cinda Biopharmaceuticals announced its glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR) dual agonist The Phase II clinical study of IBI362 in diabetic subjects completed the first subject administration


    This study is a randomized, multi-center phase II clinical study evaluating the efficacy and safety of IBI362 relative to placebo and dulaglutide in Chinese patients with type 2 diabetes.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.